Trial Profile
Bioequivalence Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex Tablet (80mg).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Aug 2011 Planned number of patients changed from 100 to NULL.
- 17 Aug 2011 New trial record